. Author manuscript; available in PMC: 2012 Jun 26.

Published in final edited form as: Mol Cancer Ther. 2009 May 5;8(5):1340–1349. doi: 10.1158/1535-7163.MCT-08-1136

Table 1.

Ability of TG and its analogues to inhibit SERCA pump, increase intracellular free calcium, decrease AR protein, and induce cell death of LNCaP cells

Analog	Amino acid	SEARCA pump inhibition	Intracellular free calcium	AR	Cell death of LNCaP

		IC₅₀	(nmol/L)^*	Protein^†	LC₅₀^‡

		(nmol/L)		(% of control)	(nmol/L)
TG	None	13 ± 2	441 ± 35	10 ± 2	10 ± 5
12ADT	None	35 ± 4	369 ± 23	14 ± 3	55 ± 12
A12ADT	Alanine	17 ± 2	410 ± 45	15 ± 4	8 ± 4
D12ADT	Aspartate	18 ± 2	385 ± 40	11 ± 6	40 ± 12
L12ADT	Leucine	45 ± 3	414 ± 44	8 ± 4	14 ± 8

NOTE: Values are the mean of a minimum of three independent experiments ± SE.

Abbreviations: A-12ADT, alanyl-12ADT; D-12ADT, asparty-12ADT; L-12DT, leucyl-12ADT.

After 10 min after exposure to 1 µmol/L TG, starting concentration was ~40 nmol/L.

^†

After 24 h of exposure to 1 µmol/L TG of LNCap cells.

^‡

After 48 h of exposure to TG.